Gilead vs Glaxo: See You In Court

The FDA approved a much-anticipated once-daily HIV medication from Gilead Sciences, ratcheting up its battle against GlaxoSmithKline for market share. Glaxo ’s response? A lawsuit.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NASDAQ:GILD NYSE:GSK Source Type: news